Compumedics (ASX:CMP) said the US Food and Drug Administration cleared the Falcon home sleep testing device to be marketed in the US, according to a Wednesday Australian bourse filing.
The device will complement the firm's Somfit technology platform. Initial sales of the platform in the last six months were around AU$1 million.
The firm is currently targeting to achieve between 10% and 30% of the addressable market over the next 24 months.
Compumedics reaffirmed its guidance for the current fiscal year of revenues of at least AU$55 million and earnings before interest, taxes, depreciation, and amortization of about AU$5 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.